Vasorelaxant effect of sildenafil on aorta and pulmonary artery in rabbits

International Journal of Pharmacology

Volumn 2, Issue 1, 2006, Pages 55-59

  Güler, Niyazi ^a   Özbek, Hanefi ^a   Eryonucu, Beyhan ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Aorta; Isolated organ bath; Pulmonary artery; Sildenafil

Indexed keywords

PHENYLEPHRINE; POTASSIUM CHLORIDE; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; IN VITRO STUDY; LUNG ARTERY; NONHUMAN; RABBIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 33644502210     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2006.55.59     Document Type: Article

References (26)

1. Morales, A., C. Gingell and M. Collins et al., 1998. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Intl. J. Impotence Res., 10: 69-74.
2. Ballard, S.A., C.J. Gingell and K. Tang et al., 1998. Effects of sildenafil on the relaxation of cyclic nucleotide phosphodiesterase isozymes. J. Urol., 159: 2164-2171.
3. Cheitlin, M.D., A.M. Hutter and R.G. Brindis et al., 1999. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and practice executive committee. Circulation, 99: 168-177.
4. Dent, G., H. Magnussen and K.F. Rabe, 1994. Cyclic nucleotide phosphodiesterases in the human lung. Lung, 172: 129-146.
5. Jackson, G., N. Benjamin and N. Jackson et al., 1999. Effects of sildenafil citrate on human hemodynamics. Am. J. Cardiol., 83: 13-20.
6. Wallis, R.M., J.D. Corbin and S.H. Francis et al., 1999. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function and the contractile responses of trabeculae carnea and aortic rings in vitro. Am. J. Cardiol., 83: 3-12.
7. Medina, P., G. Segarra and J.B. Martinez-Leon et al., 2000. Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann. Thorac. Surg., 70: 1327-1331.
8. Medina, P., G. Segarra and J.M. Vila et al., 2000. Effects of sildenafil on human penile blood vessels. Urology, 56: 539-543.
9. Prasad, S., J. Wilkinson and M.A. Gatzoulis, 2000. Sildenafil in primary pulmonary hypertension. N. Engl. J. Med., 343: 1342.
10. Abrams, D., I. Schulze-Neick and A.G. Magee, 2000. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart, 84: 4.
11. Weimann, J., R. Ullrich and J. Hromi et al., 2000. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology, 92: 1702-1712.
12. Ichinose, F., J. Erana-Garcia and J. Hromi et al., 2001. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit. Care Med., 29: 1000-1005.
13. Kleinsasser, A., A. Loeckinger and C. Hoermann et al., 2001. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am. J. Respir. Crit. Care Med., 163: 339-343.
14. Zhao, L., N.A. Mason, N.W. Morrell et al., 2001. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104: 424-428.
15. Soderling, S.H., S.J. Bayuga and J.A. Beavo, 1998. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem., 273: 15553-15558.
16. Ichinose, F., C. Adrie, W.E. Hurford et al., 1995. Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J. Appl. Physiol., 78: 1288-1295.
17. Ziegler, J.W., D.D. Ivy and J.J. Fox et al., 1998. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. Am. J. Respir. Crit. Care Med., 157: 1104-1110.
18. Takagi, M., H. Mochida and T. Noto et al., 2001. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. Eur. J. Pharmacol., 411: 161-168.
19. Eddahibi, S., B. Raffestin and A.C. Le Monnier de Gouville et al., 1998. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br. J. Pharmacol., 125: 681-688.
20. Roberts, J.D., D.M. Polener, P. Lang and W.M. Zapol, 1999. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet, 340: 818-819, 1999.
21. Van Heerden, P.V., D. Bllythe and S.A. Webb, 1996. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS- a pilot study. Anaesth. Intensive Care, 24: 564-568.
22. Loh, E., J.S. Stamler and J.M. Hare et al., 1994. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation, 90: 2780-2785.
23. Girard, C., J.J. Lehot and J.C. Pannettier et al., 1992. Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary hypertension. Anesthesiology, 77: 880-883.
24. Lee, T.S. and X. Hou, 1995. Dual effect of clonidine on isolated rabbit pulmonary arteries. Chest, 107: 793-797.
25. Cohen, A.H., K. Hanson and K. Morris et al., 1996. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest., 97: 172-179.
26. Adrie, C., W.M. Hirani and A. Holzmann et al., 1998. Selective pulmonary vasodilation by intravenous infusion of an ultrashort half-life nucleophile/nitric oxide adduct. Anesthesiology, 88: 190-195.